Silence Therapeutics plc (NASDAQ:SLN) Shares Purchased by Nantahala Capital Management LLC

Nantahala Capital Management LLC grew its stake in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 424.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,049,676 shares of the company's stock after purchasing an additional 849,676 shares during the quarter. Nantahala Capital Management LLC owned approximately 3.51% of Silence Therapeutics worth $7,222,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of SLN. JPMorgan Chase & Co. purchased a new position in shares of Silence Therapeutics during the fourth quarter worth about $26,000. Barclays PLC increased its holdings in shares of Silence Therapeutics by 83.8% in the fourth quarter. Barclays PLC now owns 6,126 shares of the company's stock valued at $42,000 after purchasing an additional 2,793 shares during the period. GAMMA Investing LLC raised its stake in shares of Silence Therapeutics by 609.2% during the fourth quarter. GAMMA Investing LLC now owns 6,092 shares of the company's stock worth $42,000 after purchasing an additional 5,233 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in Silence Therapeutics in the 4th quarter valued at $69,000. Finally, Virtus ETF Advisers LLC increased its stake in Silence Therapeutics by 130.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company's stock valued at $74,000 after buying an additional 6,098 shares during the period. Institutional investors and hedge funds own 98.73% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on SLN shares. Morgan Stanley dropped their price target on shares of Silence Therapeutics from $49.00 to $45.00 and set an "overweight" rating on the stock in a research note on Wednesday, March 5th. BMO Capital Markets cut their target price on Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating for the company in a research note on Tuesday, March 4th. HC Wainwright restated a "buy" rating and issued a $75.00 price target on shares of Silence Therapeutics in a research note on Friday, March 7th. Finally, The Goldman Sachs Group cut their price objective on Silence Therapeutics from $6.00 to $4.00 and set a "sell" rating for the company in a research report on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $40.67.

Silence Therapeutics Price Performance

SLN traded down $0.08 during trading on Friday, reaching $3.93. 423,543 shares of the stock were exchanged, compared to its average volume of 297,558. The company has a market capitalization of $117.62 million, a price-to-earnings ratio of -2.50 and a beta of 1.25. Silence Therapeutics plc has a 1 year low of $1.97 and a 1 year high of $24.38. The business's 50 day moving average price is $3.47 and its two-hundred day moving average price is $7.07.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.